Serial No.: 09/936,852



## IN THE CLAIMS

## 1. - 20. (cancelled)

21. (currently amended) An isolated haemocyanin polypeptide according to claim 20, comprising at least one amino acid sequence recombinantly expressed in a suitable host cell and selected from the following group:

```
SEQ ID NO:25 (HtH1 domain a + signal peptide),
SEQ ID NO:26 (HtH1 domain b),
SEO ID-NO:27 (HtH1 domain c),
SEQ ID NO:28 (HtH1 domain d),
SEQ ID NO:29 (HtH1 domain c),
SEQ ID NO:30 (HtH1 domain f),
SEQ ID NO:31 (HtH1 domain g),
SEQ ID NO:32 (HtH1 domain h),
SEQ ID NO:33 (partial HtH2 domain b),
SEQ ID NO:34 (HtH2 domain c),
SEQ ID NO:35 (HtH2 domain d),
SEQ ID NO:36 (HtH2 domain c),
SEQ ID NO:37 (HtH2 domain f),
SEQ ID NO:38 (HtH2 domain g),
SEQ ID NO:39 (HtH2 domain h),
SEQ ID NO:40 (partial KLH1 domain b),
SEQ ID NO:41 (KLH1 domain c),
SEQ ID NO:42 (partial KLH1 domain d),
SEQ ID NO:43 (partial KLH1 domain e),
SEQ ID NO:44 (KLH2 domain b),
```

Serial No.: 09/936,852

```
SEQ ID NO:45 (KLH2 domain c),
SEQ ID NO:46 (partial KLH2 domain d),
SEQ ID NO:47 (KLH2 domain g),
SEO ID NO:48 (partial KLH2 domain h),
SEQ ID NO:63 (HtH1 domain a' + signal peptide),
SEQ ID NO:64 (HtH1 domain h'),
SEQ ID NO:65 (partial HtH2 domain a),
SEQ ID NO:66 (HtH2 domain b'),
SEQ ID NO:67 (HtH2 domain d'),
SEQ ID NO:68 (HtH2 domain e'),
SEQ ID NO:69 (partial KLH1 domain b'),
SEQ ID NO:70 (KLH1 domain e'),
SEQ ID NO:71 (KLH1 domain f),
SEQ ID NO:72 (KLH1 domain g),
SEO ID NO:73 (KLH1 domain h),
SEQ ID NO:74 (KLH2 domain b),
SEQ ID NO:75 (KLH2 domain c'),
SEQ ID NO:76 (KLH2 domain d'),
SEQ ID-NO:77 (KLH2 domain e),
SEQ ID NO:78 (KLH2 domain f),
SEQ ID NO:79 (KLH2 domain g'),
```

or a sequence that shows at least 90% homology to one of the amino acid sequences according to SEQ ID NOs 69-73 or 40-43 over a partial region of 90 amino acids.

or a fragment of one of these sequences which has the immunological properties of at least one domain of a haemocyanin.

22. - 26. (cancelled)

27. (currently amended) [[A]] The recombinant haemocyanin polypeptide according to claim 21, characterized in that the haemocyanin polypeptide comprises either the sequences SEQ ID NO: 40 to 43 or the sequences SEQ ID NO:40 to 43 and SEQ ID NO:71 to 73 and is KLH1 from Megathura crenulata, it being possible in each case the for sequence with SEQ ID NO:40 to be replaced by SEQ ID NO:66 and/or SEQ ID NO:43 to be replaced by SEQ ID NO:70.

## 28. (cancelled)

- 29. (currently amended) The [[R]]recombinant haemocyanin polypeptide according to claim\_21 [[20]], characterized in that it is bonded covalently to viruses, virus constituents, bacteria, bacteria constituents, DNA, DNA constituents, inorganic or organic molecules, such as e.g. carbohydrates, peptides and/or glycoproteins.
- 30. (currently amended) The [[R]]recombinant haemocyanin polypeptide according to claim 21 [[20]], characterized in that the haemocyanin polypeptide is non-glycosylated.
- 31. (currently amended) The [[R]]recombinant haemocyanin polypeptide according to claim 21 [[20]], characterized in that the haemocyanin polypeptide is glycosylated.

## 32. - 44. (cancelled)

Serial No.: 09/936,852

Please add new claims 45- 49 as follows:

- 45. (new) A pharmaceutical composition, comprising an isolated recombinant haemocyanin polypeptide according claim 21, and physiologically tolerated additives.
- 46. (new) The pharmaceutical composition according to claim 45, characterized in that it is used as an antiparasitic composition, antivirus composition or as an antitumor composition.
- 47. (new) The pharmaceutical composition according to claim 45, characterized in that it is used for treatment of one of the following diseases: schistosomiasis, high blood pressure, surface bladder carcinomas, epithelial carcinomas, ovarian carcinoma, mammary carcinoma, bronchial carcinoma and colorectal carcinoma.
- 48. (new) The pharmaceutical composition according to claim 45, characterized in that it is used as a vaccine.
- 49. (new) The pharmaceutical composition according to claim 45, characterized in that it is used for prevention of cocaine abuse.